Breaking Barriers in Myelofibrosis Management: Optimizing Today, Preparing for Tomorrow

This activity was originally presented as a Post-HOPA Virtual Symposium.

Program Description

Myelofibrosis is a progressive myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, splenomegaly, debilitating constitutional symptoms, and risk of leukemic transformation. JAK inhibitors (JAKis) have become the cornerstone of myelofibrosis therapy, yet optimizing their use required oncology pharmacists to understand each agent's distinct efficacy and safety profile. Though ruxolitinib remains the foundational therapy, fedratinib, pacritinib, and momelotinib have expanded treatment options for patients with specific challenges such as severe thrombocytopenia or MF-associated anemia. Despite these advances, oncology pharmacists face complex clinical decisions surrounding patient-specific JAKi selection, evidence-based dosing and titration strategies, and the proactive management of JAKi-induced cytopenias as well as nonhematologic toxicities. The discussion will encompass approaches to navigate treatment sequencing when patients experience suboptimal responses or intolerable toxicity, with attention to safe transition strategies including tapering, overlap periods, and dose adjustments to preserve therapeutic benefit while minimizing risk. Looking beyond currently approved therapies, a growing pipeline of investigational agents holds the potential to modify disease course as evidenced by emerging endpoints such as spleen volume reduction and overall survival benefit. This program will review evidence-based and practical frameworks needed for oncology pharmacists to individualize therapy selection, optimize toxicity management, and anticipate the evolving myelofibrosis treatment landscape.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 28, 2026
Expiration date: April 28, 2027
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine current and emerging therapeutic options for myelofibrosis to guide patient selection and evidence-based sequencing across diverse clinical presentations
• Adapt dosing strategies, titration schedules, and drug–drug interactions to guide safe transitions between JAK inhibitors
• Apply evidence-based strategies to optimize dosing, enhance efficacy, and prevent, monitor, and manage treatment-related adverse effects associated with current and emerging myelofibrosis therapies
• Analyze recent clinical trial data of emerging therapies for myelofibrosis to inform treatment selection, counsel stakeholders, and prepare for their integration into clinical practice

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-26-100-H05-P. The activity is available for CE credit through April 28, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Firas El Chaer, MD, MSHCM , has the following relevant financial relationships with ineligible companies to disclose:

Grant/Research Support: Amgen, Arog Pharmaceuticals, BioSight Ltd, Bristol Myers Squibb, Celgene, FibroGen, MEI Pharma, Novartis AG, PharmaEssentia, Sanofi, SPD Oncology

Consultant: Amgen, AbbVie, Bristol Myers Squibb, CTI BioPharma, Daiichi Sankyo, Geron, Merck, Novartis, PharmaEssentia, Sobi, SPD Oncology, Syndax, Taiho Oncology

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Deidra R. Smith, PharmD, BCOP

Amy L. Morris, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Liza Patel, PharmD, RPh; Rose Buszka, PharmD, BCPS, CHCP; Adam C Welch, PharmD, MBA, FAPhA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms